Review Article

Nuclear protein of the testis midline carcinoma of the thorax

Ayae Saiki1, Keita Sakamoto1,*, Yuan Bee2, and Takehiro Izumo1

1Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan and 2Department of Pathology, Japanese Red Cross Medical Center, Tokyo, Japan

*For reprints and all correspondence: Keita Sakamoto, Department of Respiratory Medicine, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan. E-mail: sakasaka1013@gmail.com

Received 7 January 2022; Editorial Decision 28 February 2022; Accepted 2 March 2022

Abstract

Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare tumor that typically presents in the head, neck, and chest region. It primarily affects children and young adults and is rapidly progressive and lethal. Reportedly, the prognoses of NMCs of the head and neck improve following aggressive initial surgical resection +/− postoperative chemoradiotherapy (CRT) or radiotherapy (RT). However, as NMC of the thorax was identified later, treatments to improve its prognosis are yet to be identified. Our review reveals that NMC is an extremely rare cancer, and most patients remain undiagnosed. Furthermore, this review outlines the clinical characteristics of NMC of the thorax and the prospects for its treatment.

Key words: lung medicine, thoracic-mediastinum, pleura, head and neck

Introduction

Discovery of t(15;19) cancer

Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare tumor that typically presents in the head, neck, and chest region. It primarily affects children and young adults and is rapidly progressive and lethal. NMC is characterized by rearrangement of the NUTM1 gene, which generally results from a translocation of NUTM1 on chromosome 15q14 and BRD4 on chromosome 19p13 (1).

Thymic carcinoma harbouring a t(15;19)(q14;p13) translocation was first reported in Japan in 1991 (2). Thereafter, three more cases with a similar translocation were reported in the 1990s and early 2000s (3–5). In 2018, French acquired the Ty-82 cell line that generally results from a translocation of NUTM1 on chromosome 15q14 and BRD4 on chromosome 19p13 (1).

NMC registry

The International NMC registry was formed by Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital and Harvard Medical School to increase NMC awareness. In 2019, Chau et al. (9) reported the clinical characteristics of 141 cases included in this registry.

The NMC registry included 67 males and 74 females, and the median age at NMC onset was 23.6 years. The primary site was the thorax in 50% of patients, head and neck in 41% and bone and soft tissue in 6% of patients. At the time of NMC diagnosis, metastasis was identified in 50% of the patients. Most of the cases were BRD4-NUT fusion (70%), followed by BRD3-NUT (13%) and NSD3-NUT (5%) (Table 1). The median survival time was 6.5 months.

Three statistical risk groups, classified by dissection site and NUT fusion gene type, have been identified. Nonthoracic primary with non-BRD4–NUT fusion confers the best prognosis, followed by nonthoracic primary with BRD4–NUT. Thoracic NMC, regardless of the NUT fusion, has the worst prognosis (9). The prognoses of NMCs of the head and neck have been reported to improve following aggressive initial surgical resection +/− post-operative chemoradiotherapy (CRT) or radiotherapy (RT) (10). However, because NMC of the thorax was diagnosed later, treatments to improve its prognosis have yet to be identified. Thus, we investigated the clinical features of primary thoracic NMC.
**Table 1. Clinical features of NUT midline carcinoma registry**

| Registry | Number of patient | Percentage (%) |
|----------|-------------------|----------------|
| Total number of patient | 141 | 6.5 |
| Survival time (month) | 23.6 (18 days–80 years) | |
| Age (years old) | | |
| <18 | 47 | 33 |
| ≥18 | 77 | 55 |
| Unknown | 17 | 12 |
| Sex | | |
| Male | 67 | 48 |
| Female | 74 | 52 |
| Primary tumour site | | |
| Thoracic | 71 | 50 |
| Head and neck | 58 | 41 |
| Bone and soft tissue | 9 | 6 |
| Other | 2 | 1 |
| Unknown | 1 | 0.7 |
| Metastasis | | |
| Yes | 71 | 50 |
| No | 42 | 30 |
| Unknown | 28 | 20 |
| Chemotherapy | | |
| Yes | 105 | 74 |
| No | 12 | 9 |
| Unknown | 24 | 17 |
| Radiation | | |
| Yes | 85 | 60 |
| No | 32 | 23 |
| Unknown | 24 | 17 |
| Surgery | | |
| Yes | 60 | 43 |
| No | 58 | 41 |
| Unknown | 24 | 17 |
| Gene fusion | | |
| BRD4-NUTM1 | 99 | 70 |
| BRD3-NUTM1 | 19 | 13 |
| NSD3-NUTM1 | 7 | 5 |
| ZNF532-NUTM1 | 1 | 0.7 |
| ZNF592-NUTM1 | 1 | 0.7 |
| Unknown | 9 | 6 |

**Table 2. Clinical features of NUT of the thorax investigation**

| NMC of the thorax | Number of patient | Percentage (%) |
|--------------------|-------------------|----------------|
| Total number of patient | 65 | 6.75 |
| Survival time (month) | 30.0 (5–70 years) | |
| Age (years old) | | |
| <18 | 12 | 18 |
| ≥18 | 53 | 82 |
| Unknown | 0 | 0 |
| Sex | | |
| Male | 34 | 52 |
| Female | 30 | 46 |
| Unknown | 1 | 2 |
| Primary tumour site | | |
| Lung | 40 | 62 |
| Mediastinum | 19 | 29 |
| Thymus | 2 | 3 |
| Unknown | 4 | 6 |
| Metastasis | | |
| Yes | 29 | 44 |
| No | 20 | 31 |
| Unknown | 16 | 25 |
| Chemotherapy | | |
| Yes | 43 | 66 |
| No | 6 | 9 |
| Unknown | 16 | 25 |
| Radiation | | |
| Yes | 26 | 40 |
| No | 20 | 31 |
| Unknown | 19 | 29 |
| Surgery | | |
| Yes | 14 | 22 |
| No | 32 | 49 |
| Unknown | 19 | 29 |
| Gene fusion | | |
| BRD4-NUTM1 | 23 | 35 |
| BRD3-NUTM1 | 2 | 3 |
| NSD3-NUTM1 | 3 | 5 |
| Variants | 4 | 6 |
| Unknown | 33 | 51 |
| Symptoms | | |
| Yes | 44 | 68 |
| No | 6 | 9 |
| Unknown | 15 | 23 |
| Cough | 27 | 42 |
| Chest pain | 18 | 28 |
| Shortness of breath | 14 | 22 |
| Back pain | 12 | 18 |
| Fever | 8 | 12 |
| Blood sputum | 6 | 9 |
| Weight loss | 5 | 8 |
| Smoking | | |
| Yes | 16 | 25 |
| No | 15 | 23 |
| Unknown | 34 | 52 |

**NMC of the thorax**

We investigated the clinical features of primary thoracic NMC within the past 15 years (NMC of the thorax investigation) by searching for the terms ‘NUT midline carcinoma lung’ or ‘NUT midline carcinoma mediastinum’ in the PubMed database (https://pubmed.ncbi.nlm.nih.gov/) between 2006 and 2021. The International NMC registry only included data from 1993 to 2007, and because our investigation of NMC of the thorax included cases reported between 2006 and 2021, some cases may have overlapped. Our literature search identified 28 articles describing the clinical features of NMC (11–38). After reviewing these articles describing the clinical features of NMC, we decided to describe 11 clinical features (chief complaint, sex, age at diagnosis, smoking history, primary site, presence or absence of distant metastasis at the time of initial diagnosis, treatment (chemotherapy, RT, surgery), survival after diagnosis and type of genetic mutation). Because few papers mentioned all 11 items, we chose papers describing cases in which at least four of the 11 items were mentioned.

There were 65 cases that met the above requirements: 19 cases from 19 case reports and 46 cases from four review articles (Table 2). Two respiratory physicians (Saiki A. and Sakamoto K.) carefully reviewed the clinical characteristics, age, and primary site of each case to determine whether there were any duplicated cases. If so, one of the cases was subsequently removed from the study cohort. This
review outlines the clinical features of NMC of the thorax and the prospects for its treatment.

**Clinical features**

The main complaints have not mentioned in the NMC registry. In our NMC of the thorax investigation, the main complaints were cough, chest pain and dyspnea.

Our NMC of the thorax investigation included 34 males, 30 females and one case with sex unknown. As with the NMC registry, no gender bias was observed.

The age at diagnosis ranged from 5 to 70 years, with a median of 30.5 years (mean ± standard deviation, 30.0 ± 15.98) in our NMC investigation. Compared with the NMC registry data, the median age diagnosis increased from 23 to 30.5 years. This age discrepancy was because antibodies were previously only used for younger patients, but in the past 15 years, these were also used for older patients (10).

Smoking history has not been mentioned in the NMC registry. In our NMC of the thorax investigation, smokers and nonsmokers comprised 16 (25%) and 15 (23%) of the patients, respectively, while the smoking status of 34 (52%) patients was unknown.

The primary site was the lungs in 62% of all cases (40/65) in our NMC of the thorax investigation, which was similar to the NMC registry (51%). However, many cases had distant metastases at diagnosis, which could have made it difficult to determine the primary site.

In addition, 44% (29/65) of cases in our NMC of the thorax investigation had distant metastases at the time of initial diagnosis, which was similar to that in the NMC registry (50%).

The percentage of BRD4-NUT fusion genes was 71% in our investigation, which was almost the same as that in the registry (78%). The proportion of fusion genes appears to have remained unchanged during the past 15 years.

Section 6 will discuss two more items: treatment (chemotherapy, RT, and surgery) and survival after diagnosis.

**Biology**

BRD4 is a member of the BET (bromodomain and extra-terminal) protein family. It recognizes acetylated lysine in histone and functions as a transcription activator. NUT is a poorly understood protein that recruits and activates the histone acetyltransferase p300. BRD4-NUT is the only oncoprotein that drives NMC growth. Whole-genome and targeted next-generation sequencing (NGS) have revealed that besides the NUT fusion gene, NMCs are genomically stable (39).

Massive contiguous regions of chromatin coenriched with BRD4-NUT, p300, and acetylated histones are termed megadomains (MDs). BRD4-NUT binds a small region of acetylated histones and recruits p300 to locally acetylate nearby histones, resulting in further recruitment of BRD4-NUT and p300. This is termed the feed-forward model. The targets of MDs include three stem cell-related transcription factors frequently implicated in cancer: MYC, SOX2, and P63. These three transcription factors are involved in maintaining the stem cell state and preventing cell differentiation (Fig. 3). Notably, the MYC gene is directly upregulated by BRD4-NUT. Thus, NMC is considered an MYC-driven cancer (39). Eagen and French (39) proposed that MD-mediated upregulation of p63 (ΔNp63) counteracts p53 by inhibiting its transcriptional targets and preventing apoptosis.

**Diagnosis and pathology**

NMC is diagnosed by a NUT immunohistochemical (IHC) assay that stains the nuclei of NMC cells and has a specificity of 100% and sensitivity of 87% for the diagnosis of NMC, using monoclonal rabbit antibody to NUT (clone C52B1, Cell Signalling Technology, Danvers, MA, USA). Tumours where >50% of nuclei are IHC-positive on formalin-fixed, paraffin-embedded sections are considered NMC (Fig. 2). Detecting the BRD4-NUT fusion gene by reverse-transcription polymerase chain reaction, fluorescence in situ hybridization or NGS is unnecessary (40).

Pathologically, NMC is an undifferentiated carcinoma that can exhibit abrupt squamous differentiation in 33–40% of cases. Immunostaining is often positive for epithelial markers, such as cytokeratin AE1/AE3, CK5/6, p63, p40 and EMA (28). The presence of abrupt squamous differentiation can be helpful in distinguishing NC from other poorly differentiated neoplasms or Ewing sarcoma, thymic carcinoma or small-cell carcinoma. However, it is also a characteristic of basaloid squamous cell carcinoma and human papillomavirus (HPV)-associated squamous cell carcinoma of the oropharynx. Viral aetiology, such as HPV or Epstein–Barr virus (EBV), is not associated with NMC. Therefore, it can be used to exclude NMC, which sometimes lacks squamous differentiation. A key characteristic that distinguishes NMC from other poorly differentiated carcinomas is the monomorphism of the cells, which contrasts with the pleomorphism observed in other carcinomas (Fig. 1). Although the histologic features of NMC are inadequate for diagnosis, NUT IHC is recommended to rule out NMC in all undifferentiated carcinomas, with or without squamous differentiation, which have a monomorphic appearance, in the absence of EBV or HPV within the tumour (41). Generally, it is extremely rare to find NMCs with glandular differentiation; thus, these tumours do not need to be tested. The presence of neuroendocrine differentiation or TTF-1 positivity has been reported in NMCs (21,36).

**Epidemiology**

During the 14 years (1993–2007) of the NMC registry, 141 patients were diagnosed, including 71 primary thoracic NMC patients. Our NMC of the thorax investigation revealed 65 cases of primary thoracic NMC over the past 15 years (2006–2021). Although the data collection method differed, the number of cases of primary thoracic NMC has not increased significantly over the past 15 years. However, the number of cases of head and neck NMC significantly increased after 2012, when the NUT IHC assay became widely available (10).

![Figure 1. Images are 200x magnification and haematoxylin and eosin stained; proliferation of monomorphic round cells with clear cytoplasm.](Image 343x601 to 505x722)
The incidence of NMC is unknown. According to a report from the Oncology Department of the Princess Margaret Hospital for Children, located in the geographically isolated state of Western Australia, with a catchment population of around 2 million, five NMC patients were identified among all high-grade undifferentiated sarcomas or carcinomas in 0–16-year-olds from 1989 to 2014. The risk of incidence of NMC was estimated at ~0.41 per one million children (0–16 years of age). This incidence rate was independent of the primary site and limited to children (42).

The frequency of NMC among specific cancer types varied and was reported as 0.6% of non-glandular lung carcinomas (1/166) (28), 2.7% of thymic carcinomas (1/37) (43), 3.5% of poorly differentiated mediastinal carcinomas (4/114) (44) and 18% of undifferentiated carcinomas of the upper digestive tract (5/28) (45).

The probability of diagnosis varies greatly between countries. Because the diagnosis requires immunostaining and genetic analysis, many NMC patients worldwide may be undiagnosed.

**Treatment and prognosis**

In our NMC of the thorax investigation, the mean survival time after diagnosis was 6.75 months (± standard deviation 4.60). This is almost the same as the International NMC registry (6.5 months). Our method collected data on cases that could be diagnosed and treated before death, while data on cases where patients died without a diagnosis before death were not collected. Therefore, it is likely that the survival time was overestimated.

In our NMC of the thorax investigation, 40% (26/65) of patients were treated by RT. Although the details of the RT dose were unknown, RT was mostly used as a palliative treatment for stage IV patients (21/26). Curative RT, such as CRT or post-operative RT, was used in fewer than five cases.

Only 21.5% (14/65) of patients underwent partial resection or lobectomy. The mean survival period of the 13 patients whose prognosis was known was 8.8 months. While one patient died 3 days after the operation, patients operated on in the early stages of the disease displayed a better prognosis than mean survival time, 6.75 months.

There were 14 patients treated with platinum-based chemotherapy. While three patients were treated with carboplatin + paclitaxel, two were treated with cisplatin + paclitaxel, another two were treated with cisplatin + etoposide + bevacizumab and one patient each was treated with carboplatin + docetaxel, cisplatin + docetaxel, carboplatin + nab-paclitaxel. Four patients were misdiagnosed as sarcoma, treated with doxorubicin or ifosfamide. Three of four patients underwent more than four courses and survived > 9 months. Chihiro et al. (46) reported that doxorubicin or ifosfamide treatment of NMC had some effect. However, in the past 15 years, the prognosis has not been prolonged, and no effective treatment for NMC has been established.

**Future perspectives**

**BET inhibition**

BET inhibitors antagonize BRD4 and inhibit BRD4-NUT fusion. Currently, over 15 BET inhibitors are in the early phases of clinical trials (47) (Table 3). In a phase III study of molibresib (GSK525762) administered to 19 patients with NMC, two achieved PR and eight showed a stable disease (SD). Four patients who were treated for > 6 months had nonthoracic NMC. The two patients who achieved PR were BRD3-NUT fusion gene cases (48). In a phase I study of birabresib administered to 10 patients with NMC, three (30%) achieved PR and three (30%) showed SD. The three PR patients were nonthoracic primary BRD3-NUTM1 fusion gene cases (49).

In a phase I study of RO6870810, of the eight patients with NMC who were treated with RO6870810, two (25%) achieved PR, five (63%) showed SD and one (13%) showed a progressive disease (PD).

The two patients who achieved PR had primary thoracic NMC with BRD3-NUT fusion and NSD-NUT (50). In a study of BMS-986158, four NUT patients were treated with BMS-986158. One showed tumour shrinkage and 9-month clinical benefit on BMS-986158 and was a BRD3-NUT fusion case (51).

The results of the clinical trials discussed above suggest that NMCs with non-BRD4-NUT fusions may have different biological characteristics that make them more likely to be sensitive to specific BET inhibitors. Unfortunately, patients showing PR were unable to continue in these trials because of dose-limiting toxicity or the development of resistance.

BET proteins are crucial for the functioning of every cell in the body, and BET inhibitors are generally unable to selectively target cell types, targeting not only BRD4 but also BRD2 or BRD3. If BET inhibitors were able to selectively target cells, this would substantially reduce the side effects. On the other hand, the function of NUT protein is unknown and is only expressed in the testis. Thus, NUT-targeted drugs may show reduced side effects. Fertility defects in male patients are expected, but this can be addressed using assisted reproductive technology. Furthermore, the blood-testis barrier can prevent the spread of NUT-target drugs to the testes. Although the protein structure of NUT requires further elucidation, the use of an ARV-110 (a PROTAC) drug that targets NUT is promising for NMC treatment (39,52).

Proteolysis targeting chimeras (PROTACs) are also a promising treatment for NMC. PROTACs are hybrid drugs that bind to the disease-causing protein and are linked to a ubiquitin-adding enzyme that ubiquitinitates and degrades the disease-causing protein. Conventional drugs are only effective while they are bound to the target protein; therefore, they need to maintain their binding. In contrast, PROTACs irreversibly degrade the disease-causing protein after a single binding event. However, binding may be limited by their large size and, thus, limited bioavailability. A trial of ARV-110 (a PROTAC targeting androgen receptors) in patients with metastatic castration-resistant prostate cancer is currently in progress (39,52).

**P300 inhibition**

NEO2734 targets the BRD4-NUT-p300 axis to synergistically inhibit both BRD4-NUT and p300. It was significantly superior in...
| Clinical trial      | Design         | Drug       | Patients, No | Overall response rate | Median time of study | Toxicity                                                                 | Recommended dose | Publication                      |
|---------------------|----------------|------------|--------------|-----------------------|----------------------|----------------------------------------------------------------------------|--------------------|---------------------------------|
| NCT01587703        | 3 + 3, escalation | GSK525762  | 65 pts       | NMC cohort n = 19     | NMC median PFS 2.5 m | G3–4                                                                      | Safety and PK data | Piha-Paul S. et al, 2018 (41) |
|                     |                |           |              |                       |                      | Thrombocytopenia n = 24                                                   |                    |                                 |
|                     |                |           |              |                       |                      | Nausea n = 2                                                             |                    |                                 |
|                     |                |           |              |                       |                      | Alaninemia n = 3                                                         |                    |                                 |
|                     |                |           |              |                       |                      | Vomiting n = 1                                                          |                    |                                 |
|                     |                |           |              |                       |                      | Fatigue n = 3                                                            |                    |                                 |
| NCT01987362        | 3 + 3, escalation | RO6870810  | 74 pts       | PR5                   | NMC n = 2             | G3–4                                                                      | Safety and PK data | Shapiro GI, 2020 (28)            |
|                     |                |           |              |                       |                      | Thrombocytopenia n = 24                                                   |                    |                                 |
|                     |                |           |              |                       |                      | Nausea n = 2                                                             |                    |                                 |
|                     |                |           |              |                       |                      | Alaninemia n = 3                                                         |                    |                                 |
|                     |                |           |              |                       |                      | Vomiting n = 1                                                          |                    |                                 |
|                     |                |           |              |                       |                      | Fatigue n = 7                                                            |                    |                                 |
| NCT02259114        | 3 + 3, escalation | MK-862     | 46 pts       | 42 evaluable pts      | 2.3 m (0.2–15.4 m)    | G3–4                                                                      | PK data, 80 mg     | Lewin 2018 (42)                 |
|                     |                |           |              |                       |                      | Thrombocytopenia n = 24                                                   |                    |                                 |
|                     |                |           |              |                       |                      | Nausea n = 1                                                             |                    |                                 |
|                     |                |           |              |                       |                      | Alaninemia n = 3                                                         |                    |                                 |
|                     |                |           |              |                       |                      | Vomiting n = 1                                                          |                    |                                 |
|                     |                |           |              |                       |                      | Fatigue n = 3                                                            |                    |                                 |
| NCT02419417        | 3 schedules: A (5 d on/2 d off), B (14 d on/7 d off), C (7 d on/4 d off) | BMS 96158 | 75 pts       | 1 pt NUT (schedule A) | 1 pt with SD,               | G3–4                                                                      | Safety and PK data | Hilton J. et al, 2018 (45)      |
|                     |                |           |              |                       |                      | Thrombocytopenia n = 24                                                   |                    |                                 |
|                     |                |           |              |                       |                      | Nausea n = 2                                                             |                    |                                 |
|                     |                |           |              |                       |                      | Alaninemia n = 3                                                         |                    |                                 |
|                     |                |           |              |                       |                      | Vomiting n = 1                                                          |                    |                                 |
|                     |                |           |              |                       |                      | Fatigue n = 1                                                            |                    |                                 |

CRC = colorectal cancer  
CRPC = castration-resistant prostate cancer  
NSCLC = Non-Small Cell Lung Cancer  
uPR = unconfirmed partial response
Histone deacetylase inhibition

The inhibition of histone deacetylase (HDAC) activity is predicted to spread acetylation across the genome, including regions not occupied by MDs. Thus, HDAC inhibitors should result in BRD4-NUT, which binds to acetylated histones, spreading to areas of newly acetylated chromatin. Because there are limiting quantities of p300, relative depletion of p300 in MDs and MD function deteriorates, resulting in the loss of expression of pro-growth MD target genes. The clinical benefits of HDAC (vorinostat) have been confirmed (54,55).

CUDC-907 is a dual HDAC and phosphoinositide 3-kinase inhibitor. A phase I study of CUDC-907 (NCT02307240) was conducted for NMC patients. However, HDAC inhibitors display poor efficacy in solid tumours compared with haematological malignancies. This is thought to be due to the poor pharmacokinetics of HDAC inhibitors, which are unable to reach therapeutic concentrations in vitro (56).

Cyclin-dependent kinase 9 inhibition

Because cyclin-dependent kinase (CDK) 9 inhibition selectively kills NMC cells, Bragelmann et al. (57) suggested CDK9 inhibition as a treatment for NMC.

CDK4/6 inhibition

MYC is well known to promote cancer growth by upregulating and activating CDK4/6 and cyclin D1. Liao et al. (58) discovered that CDK4/6 inhibitors synergize with BET inhibitors in NMC. CDK4/6 inhibitors are in use and effective in treating oestrogen-positive breast cancer.

Conclusion

NMC is an extremely rare cancer, and it is thought that many patients remain undiagnosed. As more patients become diagnosed and are given promising treatments, it is hoped that a successful treatment will be established.

Supplementary Material

Supplementary material is available at Japanese Journal of Clinical Oncology online.

Conflict of interest statement

None declared.

References

1. French CA. NUT carcinoma: Clinicopathologic features, pathogenesis, and treatment. Pathol Int 2018;68:583–85.
2. Kubonishi I, Takehara N, Iwata J, et al. Novel t(15;19)(q15;1p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51:3327–8.

3. Kees UR, Mulcahy MT, Willoughby ML. Infrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 1991;13:3459–64.

4. Lee AC, Kwong Yi, Fu KH, et al. Disseminated mediastinal carcinoma with chromosomal translocation (15;19): a distinctive clinicopathologic syndrome. Cancer 1993;72:2273–6.

5. Vargas SO, French CA, Faul PN, et al. Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer 2001;92:1195–203.

6. French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63:304–7.

7. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22:4135–40.

8. Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, Vol. 2, 4th edn. Geneva, Switzerland: World Health Organization, 2015. Thoracic Tumours

9. Chau NG, Ma C, Danga K, et al. An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 2019;4:pkz094.

10. Chau NG, Hurwitz S, Mitchell CM, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer 2016;122:3632–40.

11. Joel S, Weschenfelder F, Schleussner E, et al. NUT midline carcinoma in a young female patient: a case report. World J Surg Oncol 2020;18:290.

12. Cao J, Chen D, Yang F, et al. NUT midline carcinoma as a primary lung tumor: a case report. J Thorac Dis 2017;9:E1045–9.

13. Zhou L, Yong X, Zhou J, et al. Clinicopathological analysis of five cases of NUT midline carcinoma, including one with the gingiva. Biomed Res Int 2020;2020:9791208.

14. Karakuzu E, Poyraz A, Oğuz Erdogan AS, et al. NUT midline carcinoma of the lung in a six-year-old child. Fetal Pediatr Pathol 2017;36:472–4.

15. Shenyo KD, Stanzione N, Caron JE, et al. Midline carcinoma expressing NUT in malignant effusion cytology. Diagn Cytopathol 2019;47:594–8.

16. Suzuki S, Kurabe N, Ohnishi I, et al. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. Pathol Res Pract 2015;211:604–8.

17. Keymel S, Krüger S. Lung cancer with prominent mediastinal lymphadenopathy - who thinks of NUT carcinoma? Pneumologie 2020;74:35–8 (in German).

18. Benito Bernáldez C, Romero Muñoz C, Almadana PV. NUT midline carcinoma of the lung, a rare form of lung cancer. Arch Bronconeumol 2016;52:619–21.

19. Harms A, Herpel E, Pfarr N, et al. NUT carcinoma of the thorax: a case report and review of the literature. Lung Cancer 2015;90:484–91.

20. Chang AI, Kim TS, Han J, et al. NUT midline carcinoma of the lung: computed tomography findings in 10 patients. J Comput Assist Tomogr 2021;45:330–6.

21. Tanaka M, Kato K, Gomi K, et al. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 2012;36:381–8.

22. Liu Y, Li YY, Ke XX, et al. The primary pulmonary NUT carcinomas and some unusual somatic mutations identified by next-generation sequencing: a case report. JNCI Cancer Spectr 2020;4:234.

23. Cavaliere S, Stathis A, Fabbri A, et al. Uncommon somatic mutations in metastatic NUT midline carcinoma. Tumori 2017;103(Suppl 1):c5–8.

24. Kuroda S, Suzuki S, Kurita A, et al. Cytological features of a variant NUT midline carcinoma of the lung harboring the NSD3-NUT fusion gene: a case report and literature review. Case Rep Pathol 2015;2015:572951.

25. Nakamura H, Tsuta K, Tsuda H, et al. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. Pathol Res Pract 2015;211:92–8.

26. Englezos J, Soller M, Panagopoulos I, Dahlén A, Dörr M, Jerkeman M. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy. BMC Cancer 2006;6:69.

27. Nelson BA, Lee EY, French CA, et al. BRD4-NUT carcinoma of the mediastinum in a pediatric patient: multidentector computed tomography imaging findings. J Thorac Imaging 2010;25:W93–6.

28. Sholl LM, Nishino M, Pokharel S, et al. Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol 2015;10:951–9.

29. Harada Y, Koyama T, Takeuchi K, et al. NUT midline carcinoma mimicking a germ cell tumor: a case report. BMC Cancer 2016;16:895.

30. Liu X, Li Y, Yu M, Zhou L. A case report of primary pulmonary NUT midline carcinoma and literature review. Zhongguo Fei Ai Za Zhi 2021;24:63–8 (in Chinese).

31. Maur M, Toss A, Dominici M, et al. Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma. Am J Case Rep 2015;16:424–9.

32. Ma Y, Feng J, Xiao X, et al. NUT midline carcinoma in the mediastinum in a ten-year-old boy. Arch Bronconeumol 2018;54:539–41.

33. Al Difallah S, Al Aukla N, Hasan S, et al. NUT midline carcinoma: a rare malignancy. Cancer Control 2017;24:202–6.

34. Wasserman JK, Purgina B, Sekhon H, et al. The gross appearance of a NUT midline carcinoma. Int J Surg Pathol 2016;24:85–8.

35. Boleti G, Perotin JM, Launois C, et al. Nuclear protein in testis carcinoma of the mediastinum: a case report. J Med Case Reports 2017;11:152.

36. Raza A, Cao H, Conrad R, et al. Nuclear protein in testis midline carcinoma with unusual elevation of α-fetoprotein and synaptophysin positivity: a case report and review of the literature. Expert Rev Anticancer Ther 2015;15:1199–213.

37. Policarpio-Nicolás ML, de Leon EM, Jagdir J. Cytologic findings of NUT midline carcinoma in the hilum of the lung. Diagn Cytopathol 2015;43:739–42.

38. Lee T, Choi S, Han J, et al. Abrupt dyskeratotic and squamoid cells in poorly differentiated carcinoma: case study of two thoracic NUT midline carcinomas with cytohistologic correlation. J Pathol Transl Med 2018;52:349–53.

39. Eagen KP, French CA. Supercharging BRD4 with NUT in carcinoma. Oncogene 2021;40:1396–408.

40. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th edn. Thoracic Tumours. Geneva, Switzerland: WHO Classification of Tumours Editorial Board editors World Health Organization, 2021.

41. French CA, NUT midline carcinoma. Cancer Genet Cytogenet 2010;203(1):16–20.

42. Carter T, Crook M, Murch A, et al. Incidence of NUT carcinoma in Western Australia from 1989 to 2014: a review of pediatric and adolescent cases from Perth Children’s hospital. BMC Cancer 2021;21:740.

43. Petrini P, French CA, Rajan A, et al. NUT rearrangement is uncommon in human thymic epithelial tumors. J Thoracic Oncol 2017;12:744–50.

44. Evans AG, French CA, Cameron MJ, et al. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012;36:1222–7.

45. Stelow EB, Belizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol 2008;32:828–34.

46. Murano C, Suzuki S, Nakamura S, et al. Vimentin-positive and alpha-fetoprotein-elevated nuclear protein of the tests midline carcinoma: a case report and review of the literature. Intern Med 2021;60:3645–9.

47. Martin-Romano P, Baldini C, Postel-Vinay S. How much can we BET on activity of BET inhibitors beyond NUT-midline carcinoma? JNCI Cancer Spectr 2019;4:pkz092.

48. Piha-Paul S, Hann CL, French CA, et al. Phase 1 study of mibrentasib (GSK523762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI cancer. Spectrum 2019.

49. Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with nirabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins,
in patients with selected advanced solid tumors. J Clin Oncol 2018; 36:3007–14.
50. Shapiro GI, LoRusso P, Dowlati A, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer 2021;124:744–53.
51. Hilton J, Cristea MC, Voskoboynik M, et al. Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins in patients with advanced cancers. Ann Oncol 2018; 19(suppl 8): viii134.
52. Hakun MC, Gu B. Challenges and opportunities in NUT carcinoma research. Genes (Basel) 2021;12:235.
53. Morrison-Smith CD, Knox TM, Filic I, et al. Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol Cancer Ther 2020;19:1406–14.
54. Maher OM, Christensen AM, Yedururi S, et al. Histone deacetylase inhibitor for nut midline carcinoma. Pediatr Blood Cancer 2015; 62:715–7.
55. Schwartz BE, Hofer MD, Lemieux ME, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011; 71:2686–96.
56. McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res 2018;138: 183–211.
57. Bragelmann J, Dammert MA, Dietlein F, et al. Systematic kinase inhibitor profiling identifies cdk9 as a synthetic lethal target in nut midline carcinoma. Cell Rep 2017;20:2833–45.
58. Liao S, Maertens O, Cichowski K, et al. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Genes Dev 2018;32:1188–200.